CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 182 enrolled
Drug / intervention
BRIMOCHOL™ PF +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05270863
NCT05270863Phase 3Completed

Multicenter, Double-Masked, Randomized, Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF Topical Ophthalmic Solution With Emmetropic Phakic and Pseudophakic Presbyopia

Visus Therapeutics·interventional·Posted Mar 8, 2022·Updated Oct 15, 2024

In Brief

A Phase 3 clinical trial evaluating BRIMOCHOL™ PF, Carbachol PF, and 1 other intervention for Presbyopia. Completed, enrolled 182 participants across 15 sites.

Detailed Summary

Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPresbyopia
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2023202420252026
First PostedMar 8, 2022
Enrollment StartMar 30, 2022
Primary CompletionMar 17, 2023
Study CompletionApr 10, 2023
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 4.3 years ago

Interventions

BRIMOCHOL™ PFdrug

A single drop in each eye at a visit.

Carbachol PFdrug

A single drop in each eye at a visit.

Brimonidine tartratedrug

A single drop in each eye at a visit.